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PERSPECTIVE

In Shortly about HIV and AIDS
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ABSTRACT
HIV is a human immunodeficiency virus, a retrovirus that causes AIDS in the event of untreated infection. The virus causes
the weakness and inability of the organism's defense system. HIV disease is a chronic progressive process that begins with the
onset of HIV virus into the body, and over time (in adults over 10 years), a gradual destruction of the immune system occurs.
The host during the infection becomes vulnerable and is suffering from complications of opportunistic infections and
malignancies. A person infected with HIV feels good until developing AIDS, does not notice any changes in health, and has
no specific external signs of infection. The only way to detect infection at this stage is HIV testing. HIV is transmitted:
unprotected sexual intercourse with the infected person, exchange of needles, syringes or accessories with infected persons
when taking drugs, with infected mother on her baby before, during or after delivery (breastfeeding).
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INTRODUCTION
The human immunodeﬁciency virus (HIV) which causes
acquired immunodeﬁciency syndrome (AIDS) is
transmitted through body ﬂuids, in particular blood,
semen, vaginal secretions and breastmilk [1].
Acronym for Acquired Immune Deficiency Syndrome,
where the body’s immunological defences are impaired by
the action of HIV (human immune deficiency virus) [2].
TESTING
Testing for HIV infection provokes ethical questions about
rights to privacy, potential discrimination, and the rights of
others not to be put at risk for HIV infection [3]. Early in
the AIDS epidemic, those at risk for infection were often
urged to be cautious about seeking testing because of a
possible loss of rights if they should be found to be
infected. In recent years, however, the availability of new
and effective treatments for HIV infection, clinical trials,
and legislated protections for those infected with the virus
have encouraged those at risk to seek testing. Such testing
is voluntary and can even be anonymous, protecting rights
to self-determination and privacy.
Informed consent has always been a requirement for HIV
testing because those at risk for infection are considered to
be competent persons with rights to self- determination. As
self-determining individuals, they also need to consider the
risks and benefits of knowing their HIV antibody status
carefully. An adequate informed consent for testing must
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include receipt of information, comprehension of the
information, and voluntariness on the part of the person to
be tested. Information that might be conveyed includes the
availability and cost of treatment for HIV infection, the
lack of a cure for AIDS, the possible stigma and
discrimination that might threaten the well-being of a
person found to be infected with HIV, and the availability
of counseling for the HIV infected. Only when the person
voluntarily agrees to testing can the test be done. If the test
is found to be positive, the individual can exercise his or
her rights to begin therapy or to enter an available clinical
trial for treatment.
The European Court of Justice decreed that HIV testing
had to be with the patient’s speciﬁc consent in order to
uphold the patient’s rights to privacy under European
Community Law [4]. Again, the underpinning belief was
that the possibility of deception would result in people who
were infected or at risk of becoming infected from seeking
appropriate medical management. Likewise compulsory
testing, detention and isolation would be an infringement
of the liberty of the affected persons.
At the time that these policies and laws were decreed there
was no vaccine and no cure for AIDS. With the
development of Highly Active AntiRetroviral Therapy
(HAART), which involves taking a variable combination
of drugs, there has been a dramatic reduction in the viral
load rendering the person less infectious to others. This
treatment delays the onset of AIDS and therefore overall
1
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mortality. The use of anti-retroviral therapy in pregnant
women has also reduced perinatal transmission. These
advances have led to a reduction in the ﬁnancial burden to
the various health systems and HIV/AIDS has been
downgraded from a ‘fatal disease’ to a ‘chronic condition’.
As a result AIDS no longer constitutes a state of
emergency in Europe. This has helped to reduce the
stigmatisation of the infection and consequently the need
for speciﬁc consent for HIV testing has had to be readdressed. It could be argued that testing without consent
is justiﬁable (both legally and ethically) in the context of
the patient’s best interests (e.g. where a person lacks
capacity, whether through mental illness/disability or in
the unconscious patient). Whether this applies to testing
for the beneﬁt of others not yet infected remains
undecided.
CONFIDENTIALITY
The protection of confidentiality has been considered
important to HIV testing in that it encourages people at risk
for HIV to come forward for testing, counseling, and
treatment [3]. Preserving confidentiality, however, can test
the duties of health professionals to protect others,
especially sexual partners of those with HIV or AIDS,
from harm. Professionals have both a moral and legal duty
to warn others who might be harmed significantly by a
patient’s actions. Applying this standard for the duty to
warn in regards to HIV infection and AIDS treatment,
however, has not been easy. The actual risk of HIV
transmission between sexual partners (thus, the
“foreseeability of harm”) is hard to quantify in each case.
In the final analysis, the health professional is expected to
weigh the likelihood of harm to other parties against his or
her duty to keep confidentiality and to act accordingly.
VIRUS
HIV destroys the human immune system, leaves millions
of adults vulnerable to a wide range of lethal illnesses in
the prime of their life and kills millions of children whose
lives have barely begun [5].
PANDEMIC
HIV morbidity and mortality has had a huge impact on
economies of LMIC (low- and middle-income countries)
[6].
RESEARCH
As the major lethal infection of the late 20th and early 21st
centuries, AIDS has generated a massive research
enterprise [3]. It is the very nature of medical research that
it produces ethical controversies. By definition, research is
activity undertaken with the intention of producing
generalizable knowledge. It, therefore, is not conducted
primarily for the benefit of the patient. In much medical
research involving sick patients, especially critically ill
patients such as those with HIV, research may be
comparing a standard treatment with one that offers
promise to be a better treatment but that may also be more
harmful. Randomized clinical trials are ethical only if there
is no reason to believe in advance that one of the treatments
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is better than the other. Hence, the randomization is never
used for the benefit of the patient.
The nurse often participates in medical and behavioral
research involving human subjects—sometimes as a
principal investigator and other times as a research team
member or advocate for the research subject [3].
Systematic research designed to test hypotheses and
generate statistically significant generalizable results is a
quite modern phenomenon. Traditionally, the primary
objective of trying new interventions was to benefit the
particular patient, especially when the usual remedies were
not producing satisfactory results. Since about the middle
of the 19th century, however, we have seen a change.
Healthcare professionals now attempt to conduct
systematically designed studies for the purpose of gaining
knowledge to benefit society or specific groups within
society, as well as the individual subjects of the
investigation.
When this new purpose is added to the agenda, a new
group of moral problems arises. The most conspicuous
problem is the potential conflict between the healthcare
professional’s traditional duty to serve the individual
patient—to benefit the patient or, as holders of newer,
more rights-oriented biomedical ethical positions would
say, to protect the rights of the patient—and the newer
interest in benefiting others.
Since the post–World War II Nuremberg trials,
researchers, potential subjects, and society at large have
been concerned about the possibility that research agendas
might conflict with traditional patient-centered
obligations. At Nuremberg, after all, it became
conspicuously clear that any investigator who approaches
a human being as a subject for the purpose of gaining
generalizable knowledge was abandoning, at least
partially, the traditional focus on the welfare and rights of
the patient. There were two major options: return to the
ethic that required the healthcare professional to work only
out of concern for the patient, or develop an ethic of
research that would permit a limited shift of attention and,
at the same time, protect the rights and interests of the
potential subject.
FUTURE
The future of HIV/AIDS presents a mixed picture [5].
While HIV/AIDS incidence has begun to level off in some
high-prevalence countries, new infections have increased
in many developed countries. While several science-based
prevention strategies need to be scaled up significantly, the
increase in mother-to-child prevention has dramatically
reduced infections among newborns and male
circumcision is a promising new prevention strategy.
While millions still lack access to treatment, there has been
a large increase in funding, drug prices have dropped
dramatically, several key drug patents will expire in the
near future and efforts to develop new treatments continue.
While stigma and discrimination remain obstacles to
effective prevention and treatment, human rights laws
have proved to be an effective vehicle for addressing
discrimination and increasing access to treatment around
the world. Thus, while HIV/AIDS continues to pose a
2
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significant threat to public health, there are many signs that
progress in fighting this pandemic can and will continue,
as knowledge gradually replaces ignorance.
CONCLUSION
The future of HIV/AIDS presents a mixed picture [5].
While HIV/AIDS incidence has begun to level off in some
high-prevalence countries, new infections have increased
in many developed countries. While several science-based
prevention strategies need to be scaled up significantly, the
increase in mother-to-child prevention has dramatically
reduced infections among newborns and male
circumcision is a promising new prevention strategy.
While millions still lack access to treatment, there has been
a large increase in funding, drug prices have dropped
dramatically, several key drug patents will expire in the
near future and efforts to develop new treatments continue.
While stigma and discrimination remain obstacles to
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effective prevention and treatment, human rights laws
have proved to be an effective vehicle for addressing
discrimination and increasing access to treatment around
the world. Thus, while HIV/AIDS continues to pose a
significant threat to public health, there are many signs that
progress in fighting this pandemic can and will continue,
as knowledge gradually replaces ignorance.
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